Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CG 0070

Drug Profile

CG 0070

Alternative Names: CG0070; CG0700

Latest Information Update: 22 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cell Genesys; Genetic Therapy
  • Developer Cold Genesys
  • Class Antineoplastics; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Granulocyte macrophage colony stimulating factor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Bladder cancer
  • Preclinical Solid tumours

Most Recent Events

  • 22 Aug 2019 Preclinical trials in Bladder cancer (Combination therapy, Metastatic disease) in USA (Intravesicular), prior to August 2019 (Cold Genesys pipeline, August 2019)
  • 22 Aug 2019 Preclinical trials in Solid tumours (Combination therapy) in USA (Intravesicular), prior to August 2019 (Cold Genesys pipeline, August 2019)
  • 12 Feb 2019 Cold Genesy withdraws a phase II trial for Bladder cancer in USA (NCT02143804)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top